Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new scanner match the gold standard in nuclear imaging?

NCT ID NCT07725237

Knowledge-focused Sponsor: GE Healthcare Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This trial compares a new SPECT/CT scanner, StarGuide GX, to a currently used reference scanner in adults who already need a SPECT/CT scan as part of their care. Each participant will receive two scans using the same tracer dose, one on each scanner, to see if the StarGuide GX produces comparable images. The goal is to collect image data and participant feedback to evaluate the new system's performance in a real clinical setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
StarGuide GX SPECT/CT Scan
What this could lead to
If successful, this could help confirm that the StarGuide GX scanner is a reliable alternative for routine SPECT/CT imaging.
What could go wrong
This is a small, early-stage device demonstration with only 30 participants, focused on data collection rather than clinical outcomes. It may not prove superiority or broad applicability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who have a clinically indicated SPECT/CT examination according to current clinical practice standards and according to the data required for the study will be enrolled in this study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult, who is at least 18 years of age, on day of consent. * Must have a clinically indicated SPECT/CT exam scheduled according to current clinical practice standards; AND * Able and willing to provide informed consent for participation in this study. Exclusion Criteria: * Who, per the site's Standard Operating Procedures (SOPs), has any condition that would prevent the clinically indicated SPECT/CT from proceeding (i.e., pregnancy, breastfeeding, renal impairment, etc.); * Who were previously enrolled in this study; * Who need urgent or emergent care; * Who have any conditions that, in the opinion of the Principal Investigator (PI) or designee, would interfere with the evaluation of the results, or constitute a health hazard for the participant; * Unwilling to have GE Healthcare personnel present during scans; OR * Unable to tolerate the exam.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spect-CT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spect-CT

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rambam Health Care Campus

    RECRUITING

    Haifa, 3109601, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.